MAM
RXRX icon

Meeder Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Meeder Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67K Sell
728
-1,242
-63% -$4.13K ﹤0.01% 904
2026
Q1 		$6.05K Buy
+1,970
New +$7.61K ﹤0.01% 795

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Meeder Asset Management's RXRX Position: Q2 2026 in Review

Meeder Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 63% in Q2 2026, selling an estimated $4.13K and leaving 728 shares worth $2.67K. The position accounts for ﹤0.01% of the portfolio, ranked #904.

Meeder Asset Management first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.05K in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Meeder Asset Management held 728 shares of Recursion Pharmaceuticals worth $2.67K as of Q2 2026.
  • Meeder Asset Management sold 1,242 Recursion Pharmaceuticals shares in Q2 2026, an estimated $4.13K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #904 holding.
  • Meeder Asset Management first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Meeder Asset Management's Recursion Pharmaceuticals position peaked at $6.05K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.